Department of Internal Medicine, North Shore University Hospital & Long Island Jewish Medical Center, New Hyde Park, NY
Xianghui Zou , Baho Sidiqi , Brooke Tortorella , Sunita Patruni , Leora Rezak , Catherine M. Alfano , Christopher Hollweg , Noah D. Kauff , Daniel King
Background: Germline genetic testing is recommended for patients with pancreatic ductal adenocarcinoma (PDAC). We identified associations between patient social profiles and delays in obtaining germline genetic testing from New York’s largest healthcare system. Methods: Patients with PDAC were identified using our EMR between Mar 2016 and Feb 2022 with an IRB-approved protocol. Median income was extrapolated using zip code. Social vulnerability index (SVI) was obtained from CDC ATSDR website. Date of diagnosis (DOD) was recorded as the date of biopsy. Delays of testing were calculated as the difference between DOD and the date of germline test. Social work needs, sources of income, and insurances were captured by EMR review of social work notes. Pearson correlation, Mann-Whitney, and Chi-square tests were used for statistical analysis. Results: We identified 104 (34%) patients with germline tests. Other than ethnicity, there was no demographic difference between patients who performed tests and patients who did not (Table). Pearson analysis between income and delays showed a negative correlation (r=-0.3033, p=0.0018). Patients who received social security and were unemployed/disabled had significant delays in testing (167d) compared to patients receiving social security and retired (30d, p=0.0318) or patients receiving salaries (13d, p=0.0002). African Americans and Hispanics, classified as underserved minority, had significant delays (92d) in testing compared to those not underserved (21d, p=0.0018). In addition, African Americans had significant delays (92d) compared to White patients (13d, p=0.0002). Patients with social work needs (12 total: 6 home care, 3 transportation, 2 financial assistance) had significant delays in testing (109d) compared to those without needs (24.5d, p=0.0028). Patients from zip codes with SVI>0.5 had non-significant delays (40.5d) compared to patients from zip codes with SVI<0.5 (26d, p=0.1817). In addition, patients with Medicare had significant delays (40d) compared to those with Medicare and supplementary insurances (15d, p=0.0205). Conclusions: PDAC patients with delays in germline testing were more likely African American and Hispanic, had lower income with social work needs, received social security, or lacked supplemental insurance. Interprofessional collaborations may be required to prompt germline tests.
N | Performed | Not Performed | p-value | ||
---|---|---|---|---|---|
302 | 104 | 198 | |||
Sex | Male Female | 126 (42%) 176 (58%) | 43 (41%) 61 (59%) | 83 (42%) 115 (58%) | >0.9999 |
Race | Asian African American White Others/Unknown | 25 (8%) 44 (15%) 169 (56%) 64 (21%) | 8 (8%) 14 (13%) 58 (56%) 24 (23%) | 17 (9%) 30 (15%) 111 (56%) 40 (20%) | 0.9262 |
Ethnicity | Non-Hispanic Hispanic Others/Unknown | 254 (84%) 20 (7%) 28 (9%) | 88 (85%) 12 (12%) 4 (4%) | 166 (84%) 8 (4%) 24 (12%) | 0.0045 |
Median Income | 95429 | 95508 | 0.9849 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Xianghui Zou
2022 ASCO Quality Care Symposium
First Author: Rebecca Ronnen
2020 Gastrointestinal Cancers Symposium
First Author: Matthew B. Yurgelun
2023 ASCO Annual Meeting
First Author: Vanessa Rosas Camargo